Amicus Price To Sales Ratio from 2010 to 2024

FOLD Stock  USD 9.96  0.02  0.20%   
Amicus Therapeutics' Price To Sales Ratio is decreasing over the years with slightly volatile fluctuation. Price To Sales Ratio is expected to dwindle to 9.96. Price To Sales Ratio is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing Amicus Therapeutics' market cap by its total sales or revenue over a 12-month period. View All Fundamentals
 
Price To Sales Ratio  
First Reported
2010-12-31
Previous Quarter
10.4878466
Current Value
9.96
Quarterly Volatility
144.30740347
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 M, Interest Expense of 52.7 M or Other Operating Expenses of 496.5 M, as well as many indicators such as Price To Sales Ratio of 9.96, Dividend Yield of 0.0 or PTB Ratio of 27.46. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Latest Amicus Therapeutics' Price To Sales Ratio Growth Pattern

Below is the plot of the Price To Sales Ratio of Amicus Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Amicus Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Amicus Therapeutics sales, a figure that is much harder to manipulate than other Amicus Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Amicus Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 6.04 X10 Years Trend
Slightly volatile
   Price To Sales Ratio   
       Timeline  

Amicus Price To Sales Ratio Regression Statistics

Arithmetic Mean90.39
Geometric Mean31.86
Coefficient Of Variation159.65
Mean Deviation99.46
Median19.51
Standard Deviation144.31
Sample Variance20,825
Range500
R-Value(0.39)
Mean Square Error18,996
R-Squared0.15
Significance0.15
Slope(12.62)
Total Sum of Squares291,545

Amicus Price To Sales Ratio History

2024 9.96
2023 10.49
2022 10.72
2021 10.26
2020 22.91
2019 12.85
2018 19.51

About Amicus Therapeutics Financial Statements

Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Sales Ratio 10.49  9.96 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out the analysis of Amicus Therapeutics Correlation against competitors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.34)
Revenue Per Share
1.629
Quarterly Revenue Growth
0.367
Return On Assets
0.0116
Return On Equity
(0.67)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.